ClinicalTrials.gg
CompletedNCT03346902Updated Jan 8, 2019Results posted

Study of EB-001 in Facial Scar Reduction

A Phase 2 interventional study of EB-001 and 0.9% Sodium Chloride Injection in Mohs Surgery, sponsored by Bonti, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Bonti, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.

Read the detailed description

This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.

The safety objective is to determine the safety and tolerability of single treatment of EB-001 when injected into facial muscles underlying a surgical wound during Mohs surgery.

The efficacy objective is to evaluate the efficacy of a single treatment of EB-001 when injected into the facial muscles (frontalis) underlying the surgical wound in improving wound healing, and reducing scar formation.

02

Conditions studied

  • Mohs Surgery
03

In context

Lead sponsor

Bonti, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 75 years of age, inclusive
  2. Subject in good health, or with stable treated medical condition, as determined by the investigator.
  3. Scheduled to undergo Mohs surgery to remove a single skin lesion in the forehead. This could be

    1. Basal Cell Carcinoma
    2. Squamous Cell Carcinoma (non-)
    3. Other suitable lesions according to the investigator opinion
  4. Lesion closure size at least 2 cm in length
  5. Women of non- must be (at least 12 consecutive months of amenorrhea)
  6. Women of childbearing potential must not be pregnant, lactating, or planning to become pregnant during the study
  7. Women of childbearing potential agreeing to use either

    1. a highly effective method of with failures rates less than 1% per year such as implant, intrauterine device (IUD), or sterilization from the day of dosing for 3 months (subjects who underwent sterilization must have initiated the procedure at least 3 months prior to the day of dosing) or
    2. dual methods of contraception with overall failures rates less than 1% per year such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3 months (subjects using oral contraception must have initiated treatment at least 2 months prior to the day of dosing)
  8. Willing and able to complete and comply with procedures, protocol requirements and instructions, which includes completion of all required visits
  9. Willing and able to sign and date IRB-approved
  10. Able to speak, read, and understand the language of the informed consent form (ICF) and study questionnaires

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast feeding, or planning a pregnancy
  2. Body weight less than 50 kg (110 pounds)
  3. Reported use of any botulinum toxin of any serotype within last 6 months before study drug administration
  4. Anticipated use of any botulinum toxin of any serotype during the study
  5. Known to any botulinum toxin serotype
  6. Known allergy or sensitivity to any of the components of the study treatments, or any materials used in the study procedures
  7. Aminoglycoside intake within 48 hours prior to or during surgery
  8. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral Sclerosis)
  9. Any uncontrolled medical condition that in opinion of investigator, puts subject at undue safety risk
  10. Any psychiatric condition that, in opinion of investigator, may interfere with study assessments or protocol compliance
  11. Any cosmetic procedure, laser resurfacing treatment, or retinoid therapy in the forehead area in the past 30 days before study drug administration
  12. Any eyebrow or eyelid ptosis at baseline as determined by the Investigator
  13. History of hypertrophic scars or keloid formation or other wound abnormalities as assessed by the investigator
  14. History of alcohol or drug abuse in the last 3 years, based on investigator judgement
  15. User or former user of nicotine-containing products, as follows:

    1. including but not limited to cigarettes, cigars, and chewing or dipping tobacco) who stopped use or consumption (i.e., smoking, chewing, or pinching) of these nicotine-containing products less than 1 year before study drug administration, or
    2. topical or oral nicotine preparations for smoking cessation within the past 90 days before study drug administration
  16. Anticipated need for surgery or overnight hospitalization during the study
  17. Current enrollment in an drug or device study or participation in such a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: : Placebo: 0.9% Sodium Chloride Injection Injection of Placebo into area of scarring (forehead)

    Drug: 0.9% Sodium Chloride Injection

  • Active comparator
    EB001

    Drug: EB-001 Injection of EB-001 into area of scarring (forehead)

    Drug: EB-001

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))

    Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score.

    Time frame: Day 30

07

Results

Posted Dec 14, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboEB001
Started48
Completed48
Not completed00

Outcome measures

PrimaryAssessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))

Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score.

Time frame:
Day 30
Reported as:
Number · Percentage reporting improvement
Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))
Percentage reporting improvementPlaceboEB001
Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))050

Adverse events

Collected over 90 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)0/4 (0%)
EB0010/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventPlaceboEB001
Asymmetry in facial features as a result of the temporal nerve being affected during the Mohs SurgerNervous system disorders0/41/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEB001Total
Mean67 (60 to 75)59 (34 to 72)62 (34 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEB001Total
Female235
Male257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEB001Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White4812
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboEB001Total
United States4812
Weight
Weight(kg)PlaceboEB001Total
Mean87.28 ± 25.52879.94 ± 19.35282.38 ± 21.055
08

Study locations

1 site
  • Northwestern University
    Chicago, Illinois 60611, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2018, 5 months.

Results were first posted in Dec 2018, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Nov 20, 2017
StartActual
Feb 6, 2018
Primary completionActual
Jul 31, 2018
CompletionActual
Oct 8, 2018
Results first posted
Dec 14, 2018
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03346902
Lead sponsor
Bonti, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Feb 6, 2018
Primary completion
Jul 31, 2018
Completion
Oct 8, 2018
Results posted
Dec 14, 2018
Last update
Jan 8, 2019

Study contacts

Earvin Liang
study director · Bonti, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type E

Start the discussion